公开(公告)号：US12251394B2

公开(公告)日：2025-03-18

申请号：US17058817

申请日：2019-05-31

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Dae-Shik Kim ,  Frank Fang ,  Atsushi Endo ,  Hyeong-Wook Choi ,  Ming-Hong Hao ,  Xingfeng Bao ,  Kuan-Chun Huang

IPC: A61K31/7084 ,  A61P35/04

Abstract: Provided herein are methods for the treatment of bladder cancer.

公开(公告)号：US20250064822A1

公开(公告)日：2025-02-27

申请号：US18941480

申请日：2024-11-08

Applicant: Epizyme, Inc. ,  Eisai R&D Management Co., Ltd.

Inventor： Heike Keilhack ,  Brett Truitt ,  Yuta Suzuki ,  Tsukasa Murase ,  Futoshi Shikata

IPC: A61K31/5377 ,  A61K9/00 ,  A61K9/20 ,  A61K9/28 ,  A61P35/00

Abstract: The present invention relates to pharmaceutical compositions comprising inhibitor(s) of human histone methyltransferase EZH2, and methods of cancer therapy using the EZH2 inhibitor(s).

公开(公告)号：US20240327535A1

公开(公告)日：2024-10-03

申请号：US18741705

申请日：2024-06-12

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Ryan Henry ,  Thiwanka Samarakoon ,  Nathan Fishkin ,  Ping Zhu ,  Ermira Pazolli ,  James Palacino ,  Juan C. Almagro

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61K47/60 ,  A61K47/65 ,  A61K47/68 ,  A61P35/00

CPC classification number: C07K16/2878 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/60 ,  A61K47/65 ,  A61K47/6803 ,  A61K47/6849 ,  A61P35/00 ,  A61K2039/505 ,  C07K2317/92

Abstract: Antibodies, antigen-binding fragments, and conjugates (e.g., antibody-drug conjugates (ADCs) such as those comprising a splicing modulator) that bind to BCMA are disclosed. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering a composition provided herein.

公开(公告)号：US20240309014A1

公开(公告)日：2024-09-19

申请号：US18480929

申请日：2023-10-04

Applicant: President and Fellows of Harvard College ,  Eisai R&D Management Co., LTD.

Inventor： Yoshito Kishi ,  Kazunobu Kira ,  Ken Ito

IPC: C07D493/22 ,  A61P35/04

CPC classification number: C07D493/22 ,  A61P35/04

Abstract: The present invention provides novel compounds (e.g., compounds of Formulae (I), (II), (III), (IV)) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or pharmaceutically acceptable salts thereof, optionally in a pharmaceutically acceptable carrier, and a medical uses thereof.

公开(公告)号：US12043670B2

公开(公告)日：2024-07-23

申请号：US17339549

申请日：2021-06-04

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Ryan Henry ,  Thiwanka Samarakoon ,  Nathan Fishkin ,  Ping Zhu ,  Ermira Pazolli ,  James Palacino ,  Juan C. Almagro

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61K47/60 ,  A61K47/65 ,  A61K47/68 ,  A61P35/00

CPC classification number: C07K16/2878 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/60 ,  A61K47/65 ,  A61K47/6803 ,  A61K47/6849 ,  A61P35/00 ,  A61K2039/505 ,  C07K2317/92

Abstract: Antibodies, antigen-binding fragments, and conjugates (e.g., antibody-drug conjugates (ADCs) such as those comprising a splicing modulator) that bind to BCMA are disclosed. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering a composition provided herein.

公开(公告)号：US12036204B2

公开(公告)日：2024-07-16

申请号：US17563162

申请日：2021-12-28

Applicant: Eisai R&D Management Co., Ltd. ,  Ono Pharmaceutical Co., Ltd.

Inventor： Taro Semba ,  Yasuhiro Funahashi ,  Takuya Suzuki

IPC: A61K31/357 ,  A61K39/395 ,  A61P35/00

CPC classification number: A61K31/357 ,  A61K39/3955 ,  A61P35/00

Abstract: A combined administration of a liposomal composition comprising Eribulin or a pharmaceutically acceptable salt thereof and a PD-1 antagonist exhibits unexpected antitumor effect.

公开(公告)号：US20230398228A1

公开(公告)日：2023-12-14

申请号：US18062996

申请日：2022-12-07

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Earl F. Albone ,  Xin Cheng ,  Daniel W. Custar ,  Keiji Furuuchi ,  Jing Li ,  Utpal Majumder ,  Toshimitsu Uenaka

IPC: A61K47/68 ,  C07K16/30 ,  A61K31/357 ,  C07K16/28 ,  C07K16/32

CPC classification number: A61K47/6803 ,  C07K16/30 ,  A61K47/6889 ,  A61K47/6849 ,  A61K31/357 ,  C07K16/28 ,  C07K16/32 ,  C07K2317/14 ,  C07K2317/40 ,  C07K2317/565 ,  C07K2317/77 ,  C07K2317/92

Abstract: Linker toxins and antibody-drug conjugates that bind to human oncology antigen targets such as folate receptor alpha and/or provide anti-tubulin drug activity are disclosed. The linker toxins and antibody-drug conjugates comprise an eribulin drug moiety and can be internalized into target antigen-expressing cells. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering the antibody-drug conjugates provided herein.

公开(公告)号：US11833146B2

公开(公告)日：2023-12-05

申请号：US16607402

申请日：2018-05-30

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Mai Miyamoto ,  Sadaharu Kotani

IPC: A61K31/4745 ,  A61P25/28 ,  A61K31/445

CPC classification number: A61K31/4745 ,  A61K31/445 ,  A61P25/28

Abstract: There is provided a therapeutic agent for Alzheimer's disease and Lewy body dementia for combined use of (S)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]quinoline-4(5H)-one represented by formula (1):




or a pharmaceutically acceptable salt thereof, and donepezil represented by formula (II):





or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230348460A1

公开(公告)日：2023-11-02

申请号：US17956435

申请日：2022-09-29

Applicant: Liverpool School of Tropical Medicine ,  The University of Liverpool ,  Eisai R&D Management Co., Ltd.

Inventor： Stephen A. Ward ,  Mark J. Taylor ,  Paul M. O’Neil ,  Weiqian David Hong ,  Farid Benayoud

IPC: C07D471/04 ,  C07D239/86 ,  C07D495/04

CPC classification number: C07D471/04 ,  C07D239/86 ,  C07D495/04

Abstract: The present invention relates to compounds of Formulae I and II as defined herein, and salts and solvates thereof.





The present invention also relates to pharmaceutical compositions comprising compounds of Formulae I and II, and to the use of compounds of Formulae I and II in the treatment or prevention of filarial worm infection, as well as other diseases or conditions in which filarial worm infection is implicated.

公开(公告)号：US11753669B2

公开(公告)日：2023-09-12

申请号：US17159655

申请日：2021-01-27

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Jared Spidel ,  Earl Albone

IPC: C07K16/00 ,  C12P21/02 ,  A61K47/68

CPC classification number: C12P21/02 ,  A61K47/68 ,  A61K47/6803 ,  A61K47/6811 ,  C07K16/00 ,  C12Y203/02013 ,  C07K2317/40 ,  C07K2317/41 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/53 ,  C07K2317/55

Abstract: Provided herein are conjugated immunoglobulins and methods for generating conjugated immunoglobulins using a microbial transglutaminase.